Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.

Hsu J, Fung V, Price M, Huang J, Brand R, Hui R, Fireman B, Newhouse JP.

JAMA. 2008 Apr 23;299(16):1929-36. doi: 10.1001/jama.299.16.1929.

PMID:
18430912
2.

Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.

Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC.

J Manag Care Spec Pharm. 2015 Oct;21(10):956-64.

3.

Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

Goedken AM, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003.

PMID:
20511109
4.

Responses to Medicare drug costs among near-poor versus subsidized beneficiaries.

Fung V, Reed M, Price M, Brand R, Dow WH, Newhouse JP, Hsu J.

Health Serv Res. 2013 Oct;48(5):1653-68. doi: 10.1111/1475-6773.12062.

5.

Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.

Conwell LJ, Esposito D, Garavaglia S, Meadows ES, Colby M, Herrera V, Goldfarb S, Ball D, Marciniak M.

Am J Geriatr Pharmacother. 2011 Aug;9(4):241-9. doi: 10.1016/j.amjopharm.2011.04.009.

PMID:
21616722
6.

An overview and study of beneficiaries' knowledge, attitudes, and perceptions of the medicare part d benefit.

Woelfel JA, Patel RA, Lee H, Chu S, Ranson C, Patel B, Italia U, Walberg MP, Carr-Lopez SM, Galal SM.

Consult Pharm. 2015 Feb;30(2):101-11. doi: 10.4140/TCP.n.2015.101..

PMID:
25695416
7.

Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.

Fung V, Mangione CM, Huang J, Turk N, Quiter ES, Schmittdiel JA, Hsu J.

Health Serv Res. 2010 Apr;45(2):355-75. doi: 10.1111/j.1475-6773.2009.01071.x.

8.

Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.

Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC.

J Manag Care Spec Pharm. 2014 Aug;20(8):862-76.

9.

Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.

Blumberg DM, Prager AJ, Liebmann JM.

JAMA Ophthalmol. 2016 Feb;134(2):212-20. doi: 10.1001/jamaophthalmol.2015.5090.

PMID:
26720853
10.

Medicare beneficiaries' management of capped prescription benefits.

Cox ER, Jernigan C, Coons SJ, Draugalis JL.

Med Care. 2001 Mar;39(3):296-301.

PMID:
11242323
11.

Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.

Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S.

PLoS Med. 2011 Aug;8(8):e1001075. doi: 10.1371/journal.pmed.1001075. Erratum in: PLoS Med. 2014 Aug;11(8):e1001716.

12.

The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?

Sacks NC, Burgess JF, Cabral HJ, McDonnell ME, Pizer SD.

J Manag Care Spec Pharm. 2015 Aug;21(8):678-87.

13.

Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.

Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM.

JAMA. 2004 Aug 25;292(8):952-60.

PMID:
15328327
14.

Patient-provider communication regarding drug costs in Medicare Part D beneficiaries with diabetes: a TRIAD Study.

Schmittdiel JA, Steers N, Duru OK, Ettner SL, Brown AF, Fung V, Hsu J, Quiter E, Tseng CW, Mangione CM.

BMC Health Serv Res. 2010 Jun 14;10:164. doi: 10.1186/1472-6963-10-164.

15.

Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs.

Fung V, Price M, Busch AB, Landrum MB, Fireman B, Nierenberg A, Dow WH, Hui R, Frank R, Newhouse JP, Hsu J.

Med Care. 2013 Jul;51(7):614-21. doi: 10.1097/MLR.0b013e31829019c5.

16.

Effects of Medicare Part D coverage gap on medication adherence.

Zhang Y, Baik SH, Lave JR.

Am J Manag Care. 2013 Jun 1;19(6):e214-24.

17.

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.

Polinski JM, Mohr PE, Johnson L.

Arthritis Rheum. 2009 Jun 15;61(6):745-54. doi: 10.1002/art.24560.

18.

Medicare Part D coverage gap and diabetes beneficiaries.

Schmittdiel JA, Ettner SL, Fung V, Huang J, Turk N, Quiter ES, Swain BE, Hsu JT, Mangione CM.

Am J Manag Care. 2009 Mar;15(3):189-93.

19.

Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.

Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, Gurwitz JH, Pierre-Jacques M, Safran DG, Adler GS, Soumerai SB.

JAMA. 2008 Apr 23;299(16):1922-8. doi: 10.1001/jama.299.16.1922.

20.

Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease.

Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ.

JAMA. 2001 Oct 10;286(14):1732-9.

PMID:
11594898
Items per page

Supplemental Content

Support Center